相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
Gareth J. Morgan et al.
BLOOD (2012)
Proteasome Inhibitors Induce p53-Independent Apoptosis in Human Cancer Cells
Bulbul Pandit et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Increased Copy Number of the Interleukin-6 Receptor Gene Is Associated with Adverse Survival in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation
Seon Young Kim et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
Nikhil C. Munshi et al.
BLOOD (2011)
Chromosomal Aberrations+1q21 and del(17p13) Predict Survival in Patients With Recurrent Multiple Myeloma Treated With Lenalidomide and Dexamethasone
Ulrike Klein et al.
CANCER (2011)
Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
Heinz Ludwig et al.
ONCOLOGIST (2011)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
Kai Neben et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling
Marc S. Raab et al.
BLOOD (2009)
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Donna Reece et al.
BLOOD (2009)
G6PD deficiency and cerebrovascular disease in sickle cell anemia? Response
Francoise Bernaudin et al.
BLOOD (2009)
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2009)
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
John D. Shaughnessy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
Wei Xiong et al.
BLOOD (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells
Emma L. Davenport et al.
BLOOD (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
S. Jagannath et al.
LEUKEMIA (2007)
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
R. Fonseca et al.
LEUKEMIA (2006)
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Ichiro Hanamura et al.
BLOOD (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
DR Carrasco et al.
CANCER CELL (2006)
Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma
L. Chiecchio et al.
LEUKEMIA (2006)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma
S Wuilleme et al.
LEUKEMIA (2005)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
